moxifloxacin has been researched along with interleukin-8 in 13 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (interleukin-8) | Trials (interleukin-8) | Recent Studies (post-2010) (interleukin-8) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 23,523 | 1,167 | 9,990 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dower, SK; Moore, LJ; Pridmore, AC; Read, RC | 1 |
| Blau, H; Fabian, I; Halperin, D; Levitov, A; Shalit, I; Weiss, T; Werber, S | 1 |
| Berger, RE | 1 |
| Fabian, I; Haite, D; Halperin, D; Levitov, A; Osherov, N; Romano, J; Shalit, I | 1 |
| Blau, H; Fabian, I; Halperin, D; Klein, K; Shalit, I | 1 |
| Fabian, I; Halperin, D; Levitov, A; Priel, E; Reuveni, D; Shalit, I | 1 |
| Buommino, E; Cozza, V; Donnarumma, G; Iovene, MR; Paoletti, I; Tudisco, L; Tufano, MA | 1 |
| Fabian, I; Halperin, D; Priel, E; Reuveni, D; Shalit, I | 1 |
| Eick, S; Guentsch, A; Hoffmann, T; Jentsch, H; Pfister, W | 1 |
| Askenasy, N; Fabian, I; Halperin, D; Reuveni, D; Shalit, I; Tsarfaty, G | 1 |
| Hao, L; He, S; Li, H; Zhu, S | 1 |
| Bellon, H; Heigl, T; Hoet, P; Lammertyn, E; Mathyssen, C; Pilette, C; Sacreas, A; Vanaudenaerde, BM; Vandermeulen, E; Verleden, GM; Verleden, SE; Vos, R; Vriens, H | 1 |
| Baba, T; Inoue, Y; Matsuura, K; Miyake, H; Miyazaki, D; Sasaki, SI; Shimizu, Y | 1 |
1 trial(s) available for moxifloxacin and interleukin-8
| Article | Year |
|---|---|
Moxifloxacin as an adjunctive antibiotic in the treatment of severe chronic periodontitis.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteroides; Chronic Periodontitis; Colony Count, Microbial; Combined Modality Therapy; Dental Scaling; Doxycycline; Female; Fluoroquinolones; Follow-Up Studies; Gingival Hemorrhage; Humans; Interleukin-8; Leukocyte Elastase; Male; Moxifloxacin; Periodontal Attachment Loss; Periodontal Pocket; Peroxidase; Porphyromonas gingivalis; Prospective Studies; Quinolines; Root Planing; Treatment Outcome; Treponema denticola | 2008 |
12 other study(ies) available for moxifloxacin and interleukin-8
| Article | Year |
|---|---|
Penicillin enhances the toll-like receptor 2-mediated proinflammatory activity of Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Choline; Colony Count, Microbial; Enzyme Inhibitors; Erythromycin; Ethanolamine; Fluoroquinolones; HeLa Cells; Humans; Interleukin-8; Membrane Glycoproteins; Moxifloxacin; N-Acetylmuramoyl-L-alanine Amidase; Penicillins; Pneumococcal Infections; Quinolines; Receptors, Cell Surface; Streptococcus pneumoniae; Toll-Like Receptor 2; Toll-Like Receptors; Transfection | 2003 |
Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Aza Compounds; Blotting, Western; Cytokines; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Fluoroquinolones; Humans; In Vitro Techniques; Interleukin-1; Interleukin-8; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Monocytes; Moxifloxacin; NF-kappa B; Quinolines; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Aza Compounds; Cell Line; Cell Movement; Chemokine CCL2; Chlamydia Infections; Chlamydophila pneumoniae; Endothelium, Vascular; Fluoroquinolones; Gatifloxacin; Humans; Interleukin-8; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytosis; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha | 2005 |
Anti-inflammatory effects of moxifloxacin on IL-8, IL-1beta and TNF-alpha secretion and NFkappaB and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspergillosis; Aspergillus fumigatus; Aza Compounds; Blotting, Western; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Fluoroquinolones; Humans; Immunosuppression Therapy; Interleukin-1; Interleukin-8; Mitogen-Activated Protein Kinases; Monocytes; Moxifloxacin; NF-kappa B; Oncogene Protein p65(gag-jun); p38 Mitogen-Activated Protein Kinases; Quinolines; Signal Transduction; Tumor Necrosis Factor-alpha | 2006 |
Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line.
Topics: Anti-Infective Agents; Aza Compounds; Azithromycin; Bronchi; Cell Line; Ciprofloxacin; Cystic Fibrosis; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fluoroquinolones; Humans; Interleukin-1beta; Interleukin-6; Interleukin-8; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Moxifloxacin; NF-kappa B; Phosphorylation; Quinolines; Tumor Necrosis Factor-alpha | 2007 |
Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Aza Compounds; Caspase 3; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; DNA, Superhelical; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Etoposide; Fluoroquinolones; Humans; Interleukin-1beta; Interleukin-8; Jurkat Cells; Moxifloxacin; Plasmids; Quinolines; Time Factors; Tumor Necrosis Factor-alpha | 2006 |
Anti-inflammatory effects of moxifloxacin and human beta-defensin 2 association in human lung epithelial cell line (A549) stimulated with lipopolysaccharide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aza Compounds; beta-Defensins; Cell Adhesion; Cell Line; Cytokines; Epithelial Cells; Fluoroquinolones; Gene Expression; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Interleukin-8; Lipopolysaccharides; Lung; Moxifloxacin; Neutrophils; Quinolines; Tumor Necrosis Factor-alpha | 2007 |
Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Camptothecin; Cell Line, Tumor; Ciprofloxacin; DNA; Fluoroquinolones; Humans; Interleukin-8; Moxifloxacin; Quinolines; Topoisomerase I Inhibitors; Vascular Endothelial Growth Factor A | 2008 |
Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.
Topics: Angiogenesis Inhibitors; Animals; Anti-Infective Agents; Antineoplastic Agents; Aza Compounds; Camptothecin; Cell Proliferation; Drug Synergism; Female; Fluoroquinolones; Humans; Interleukin-8; Irinotecan; Mice; Mice, SCID; Moxifloxacin; Neoplasms, Experimental; Platelet Endothelial Cell Adhesion Molecule-1; Quinolines; Ultrasonography, Doppler; Xenograft Model Antitumor Assays | 2010 |
Anti-inflammatory effects of moxifloxacin on rat airway smooth muscle cells exposed to allergen: Inhibition of extracellular-signal-regulated kinase and nuclear factor-κB activation and of interleukin-8 and eotaxin synthesis.
Topics: Allergens; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Asthma; Aza Compounds; Cells, Cultured; Chemokine CCL11; Dexamethasone; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fluoroquinolones; Interleukin-8; Moxifloxacin; Myocytes, Smooth Muscle; NF-kappa B; Quinolines; Rats; Tumor Necrosis Factor-alpha | 2012 |
Interleukin-1α induced release of interleukin-8 by human bronchial epithelial cells in vitro: assessing mechanisms and possible treatment options.
Topics: Acetates; Acetylcysteine; Aminopyridines; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Benzamides; Bronchi; Cell Line; Cyclopropanes; Dapsone; Dexamethasone; Dose-Response Relationship, Drug; Epithelial Cells; Fluoroquinolones; Humans; Interleukin-1alpha; Interleukin-8; MAP Kinase Signaling System; Moxifloxacin; Neutrophils; Phosphorylation; Pyridones; Quinolines; Sulfides; Theophylline; Treatment Outcome | 2017 |
Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Cell Survival; Cells, Cultured; Endothelial Cells; Esterases; Humans; Interleukin-8; Intravitreal Injections; Mice; Moxifloxacin; Pericytes; Retina; Vancomycin | 2019 |